New SMC guidance for DLBCL
The Scottish Medicines Consortium recommends loncastuximab tesirine but not axicabtagene ciloleucel as treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
The Scottish Medicines Consortium recommends loncastuximab tesirine but not axicabtagene ciloleucel as treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
New third line treatment available for relapsed or refractory diffuse large B-cell lymphoma.
New treatment available for relapsed or refractory diffuse large B-cell lymphoma.
A summary of our submission to the National Institute for Health Care and Excellence (NICE) for Evusheld.
Evusheld, the COVID-19 treatment which could prevent disease.
Venetoclax has been recommended for adults with chronic lymphocytic leukaemia.
NICE is not recommending ibrutinib for treating Waldenström’s macroglobulinaemia in adults who have had at least one previous treatment.
Venetoclax plus obinutuzumab has been approved for use in the NHS in Scotland for adults with untreated chronic lymphocytic leukaemia.
Although not available yet, we have received calls to the helpline asking for more information about a drug called Evusheld.
NICE has expanded access to pembrolizumab on the NHS.